-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Umu4eOfoy+DRnoOGywLp4WEUrKOlyd5rxOiUmfz12Yves5husmidaKPoIaw2FpYD QXqxL51ubTFEeNc1U1lnYA== 0001005477-99-005974.txt : 19991221 0001005477-99-005974.hdr.sgml : 19991221 ACCESSION NUMBER: 0001005477-99-005974 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19991220 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: BIOPOOL INTERNATIONAL INC CENTRAL INDEX KEY: 0000830736 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 581729436 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D SEC ACT: SEC FILE NUMBER: 005-40396 FILM NUMBER: 99777583 BUSINESS ADDRESS: STREET 1: 6025 NICOLLE ST SUITE A CITY: VENTURA STATE: CA ZIP: 93003 BUSINESS PHONE: 8056540643 MAIL ADDRESS: STREET 1: 6025 NICOLLE STREET CITY: VENTURA STATE: CA ZIP: 93003 FORMER COMPANY: FORMER CONFORMED NAME: CYTRX BIOPOOL LTD DATE OF NAME CHANGE: 19890716 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BIOTECH INTERNATIONAL LTD CENTRAL INDEX KEY: 0001101242 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D BUSINESS ADDRESS: STREET 1: 11 DURBELL STREET STREET 2: PO BOX 391, QUEENSLAND AUSTRALIA CITY: ACACIA RIDGE ZIP: 110166 SC 13D 1 SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Biopool International, Inc. - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock - -------------------------------------------------------------------------------- (Title of Class of Securities) 90649104 - -------------------------------------------------------------------------------- (CUSIP Number) Mr W Randolph, Biotech International Limited, PO Box 391 Acacia Ridge Qld 4110 Australia Tel: +61-7-3370-6396 Fax: +61-7-3370-6370 - -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) December 9, 1999 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [ ] CUSIP No. 90649104 - -------------------------------------------------------------------------------- 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Biotech International Limited - -------------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) |_| (b) |_| - -------------------------------------------------------------------------------- 3. SEC Use Only - -------------------------------------------------------------------------------- 4. Source of Funds WC BK - -------------------------------------------------------------------------------- 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) |_| - -------------------------------------------------------------------------------- 6. Citizenship or Place of Organization Australia - -------------------------------------------------------------------------------- Number of Shares Beneficially Owned by Each Reporting Person With 7. Sole Voting Power 492,700 - -------------------------------------------------------------------------------- 8. Shared Voting Power - -------------------------------------------------------------------------------- 9. Sole Dispositive Power 492,700 - -------------------------------------------------------------------------------- 10. Shared Dispositive Power - -------------------------------------------------------------------------------- 11. Aggregate Amount Beneficially Owned by Each Reporting Person 492,700 - -------------------------------------------------------------------------------- 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) |_| - -------------------------------------------------------------------------------- 13. Percent of Class Represented by Amount in Row (11) 5.95% - -------------------------------------------------------------------------------- 14. Type of Reporting Person CO - -------------------------------------------------------------------------------- 2 CUSIP No. 90649104 Schedule 13D Item 1. Security and Issuer This statement relates to Common Stock, par value $0.01 per share (the "Common Stock") of Biopool International, Inc, a Delaware corporation (the "Issuer"). The Issuer's principal executive offices are located at 6025 Nicolle Street Ventura, CA 93003. Item 2. Identity and Background The name, place of organization and business address of the person filing this Statement is: Biotech International Limited, a corporation organized under the laws of Australia ("Biotech International"), of 11 Durbell Street Acacia Ridge Queensland 4110 Australia. Biotech International develops, manufactures and sells human and veterinary diagnostics. It also is in the process of developing an industrial paper bleach enzyme for eventual manufacture and sale. Its operations are based in Australia. In its last fiscal year a large proportion of its sales of products were to overseas markets. The name, principal occupation, business address and citizenship of each of the executive officers and directors of Biotech International are as follows: Mr David R Fawcett (Chairman), Company Director, 11 Flannan Place Warwick Western Australia 6024 , Citizen of Australia. Mr Clive Little (Deputy Chairman), Company Director, 123 Gipps Street East Melbourne Victoria 3002 Australia, Citizen of Australia. 3 Mr Neville J Bassett (Director), Corporate Consultant, 23 Priory Road Maida Vale Western Australia 6057 Australia, Citizen of Australia. Mr Peter M Dowding (Director), Barrister at Law, 32 Kinninmont Avenue Nedlands Western Australia 6009 Australia, Citizen of Australia. Mr Roman Zwolenski (Executive Director), Company Manager, 50a Broomfield Street Taringa Queensland 4068 Australia, Citizen of Australia. Mr Warren A Randolph (Company Secretary), Corporate Consultant & CPA, 34 Fleetwood Street Macgregor Queensland 4109 Australia, Citizen of Australia. Neither Biotech International nor, to the best of the knowledge of Biotech International, any of its executive officers or directors has, during the last five years, (a) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (b) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. Item 3. Source and Amount of Funds or Other Consideration All of the Common Stock acquired by Biotech International has been purchased on the OTC Bulletin Board market on various dates. Biotech International acquired the Common Stock with a combination of cash on hand and borrowed funds. The borrowed funds were loaned to Biotech International in the ordinary course of business pursuant to a general credit facility provided to Biotech International by the Australia and New Zealand Banking Group Limited. Item 4. Purpose of Transaction Biotech International acquired the Common Stock of the Issuer to gain an investment interest in the Issuer. In the course of strategic planning, Biotech International has determined to increase its investment in the Issuer. Biotech International reserves the right to exercise any and all of its rights and privileges as a security holder of the Issuer. However, except as set forth in this Item 4, Biotech International has no present plan or proposal that relates to or would result in (i) the disposition of securities of the Issuer by any person, (ii) an extraordinary corporate transaction, such as a merger, reorganization, liquidation, or sale or transfer of a material amount of assets involving the Issuer or any of its subsidiaries, (iii) any material change in the Issuer's present capitalization or dividend policy or any other material change in the Issuer's business or corporate structure, (iv) any change in the Issuer's charter or bylaws or other actions that may impede the acquisition of control of the Issuer by any person, (vi) a class of equity securities of the Issuer becoming eligible for termination of 4 registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended, or a class of securities of the Issuer ceasing to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association or (vi) any similar action. Item 5. Interest in Securities of the Issuer (a) and (b) Biotech International currently has ownership of 492,700 shares of Common Stock of the Issuer. This amount constitutes approximately 5.95% of the issued and outstanding shares of Common Stock of the Issuer, based upon the total of 8,286,986 issued and outstanding shares as of December 15, 1999. Biotech International has the sole power to direct the vote of and sole power to direct the disposition of the 492,700 shares of Common Stock. (c) During the past 60 days, Biotech International has made the following purchases of Common Stock of the Issuer on the OTC Bulletin Board: Date Common Stock purchased Price paid each - ---- ---------------------- --------------- October 29, 1999 15,000 81.250 cents November 1, 1999 15,000 81.250 cents November 4, 1999 10,000 84.375 cents November 5, 1999 36,850 84.375 cents November 10, 1999 23,500 87.500 cents November 12, 1999 10,000 87.500 cents November 12, 1999 27,500 90.625 cents November 12, 1999 2,500 90.000 cents November 16, 1999 10,000 90.000 cents November 17, 1999 25,000 86.875 cents November 18, 1999 20,000 89.063 cents November 23, 1999 11,500 90.353 cents November 26, 1999 97,500 90.625 cents November 29, 1999 5,000 90.625 cents December 1, 1999 9,350 90.625 cents December 2, 1999 5,000 93.750 cents December 3, 1999 21,500 92.660 cents December 9, 1999 20,000 93.750 cents December 10, 1999 10,000 87.500 cents December 10, 1999 15,000 90.625 cents December 13, 1999 10,000 90.625 cents December 14, 1999 40,000 90.625 cents (d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock held by Biotech International. (e) Not applicable. 5 Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. None Item 7. Material to be Filed as Exhibits None SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated December 15, 1999 Signature: /s/ Warren A. Randolph --------------------------------- Name/Title: Warren A Randolph, Company Secretary, Biotech International Limited -----END PRIVACY-ENHANCED MESSAGE-----